MEDIAN TECHNOLOGIES Aktie

 

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF's General Regulations.SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares 36,948,314 Number of real voting rights* (excluding treasury shares**) 36,878,376 Theoretical number of voting rights* (including treasury shares**) 36,925,114 (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF's General Regulations About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel...

Record iCRO bookings in 2025; order backlog at an all-time high of €76.6 million despite negative forex impact of € (6.5) million 2025 revenue of €23.5 million, up 2.6% vs 2024 despite negative forex impact of € (0.8) million FDA decision for eyonis® LCS expected in the coming weeks; CE marking anticipated in Q2 2026 First U.S. and European distribution agreement for eyonis® LCS signed in December 2025 2026 set to accelerate commercial deployment of eyonis® LCS and expand the eyonis® portfolio As of December 31, 2025, cash position at €18.2 million after 2025 refinancing operations SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers...

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF's General Regulations.SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares 36,751,358 Number of real voting rights* (excluding treasury shares**) 36,690,400 Theoretical number of voting rights* (including treasury shares**) 36,728,158 (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF's General Regulations About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel...

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF's General Regulations. SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares 36,741,587 Number of real voting rights* (excluding treasury shares**) 36,669,667 Theoretical number of voting rights* (including treasury shares**) 36,718,387 (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF's General Regulations About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of nove...

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF's General Regulations.SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares 36,741,587 Number of real voting rights* (excluding treasury shares**) 36,659,545 Theoretical number of voting rights* (including treasury shares**) 36,718,387 (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF's General Regulations About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today that Didric Cederholm has joined its Board of Directors, chaired by Oran Muduroglu. The appointment was approved during the ordinary shareholders' meeting, held on October 30, 2025. Didric Cederholm is a Founding Partner and the Chief Investment Officer of Lion Point Capital, a global special situations investment fund. Prior to founding Lion Point Capital, Didric spent nearly eight years at Elliott Management and was previously a Principal at Eos Partners. Didric graduated in 2003 with honors from Columbia Business School, where he was a Fulbright Scholar, and has a LLM from S...

Indian engineering and data professionals saw a significant pay drop to $22,000 in 2025, a stark contrast to the US's $150,000. While gender pay gaps persist globally, India shows near parity in tech roles, with sales achieving full gender equality. Equity-based pay is increasingly driving compensation for top talent worldwide....

Operating loss reduced by €4 million in first six months of 2025 versus H1 2024, highlighting improved corporate efficiency H1 2025 revenues at €11.3 million, vs €10.9 million in H1 2024; Q3 2025 revenue at €5.9 million Order backlog at €73.6 million as of September 30, 2025, a 3% increase from June 30, 2025 Decision on FDA 510(k) clearance for eyonis® LCS marketing authorization in the U.S. expected early Q1 2026 Financed until at least Q4 2026, with €25.3 million in cash and cash equivalents as of September 30, 2025 SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today reported its consolidated financial results for the six m...

Proceeds to support the commercial launch of eyonis® LCS in the U.S. and Europe, and accelerate the broader development of eyonis®, Median's AI-powered Software as a Medical Device suite for early cancer diagnosis €20.7 million repayment of the first tranche of the 2019 EIB loan facility completed on October 17, 2025 Following these transactions, the Company's cash runway is extended through Q4 2026 SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today the receipt of a €19 million payment under the first tranche of the financial agreement executed with the European Investment Bank (EIB) on July 11, 2025, which has a total v...

Capital increase of 23.9 million euros from institutional and retail investors at a subscription price of €1.66 per ABSA Extension of the Company's cash runway until Q4 2026 SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Not to be published, distributed or disseminated, directly or indirectly, in the United States of America, Australia, Canada, South Africa and Japan Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announces the success of its capital increase targeting institutional and retail investors through a priority subscription period, a public offering, and a private placement with qualified investors (together, the “Offering”). The Offering was exclusively open to investors,...

Capital increase in the form of shares with attached warrants ("ABSA") without preferential subscription rights by way of an equity public offering and with a priority subscription period of 5 trading days on an irreducible and reducible basis for an estimated amount of €22.0 million Subscription price: €1.66 for one ABSA Subscription period of the priority subscription and the public offering from July 23, 2025 until 5:00 pm CEST on July 29, 2025 Minimum orders accepted as part of the capital increase: €100,000 per investor Subscription commitments received of approximately €17.2 million (78 % of the offering) Net proceeds of the transaction are intended to support eyonis® Lung Cancer Screening (LCS) Software as a Medical Device's commercial launch, sales ramp-up in U.S., as well as the expansion of the eyonis® suite of products for image-based early cancer diagnosis SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: This press release cancels and supersedes the press releas...

Capital increase in the form of shares with attached warrants ("ABSA") without preferential subscription rights by way of an equity public offering and with a priority subscription period of 5 trading days on an irreducible and reducible basis for an estimated amount of €22.0 million Subscription price: €1.66 for one ABSA Subscription period of the priority subscription and the public offering from July 23, 2025 until 5:00 pm CEST on July 29, 2025 Subscription commitments received of approximately €17.2 million (78 % of the offering) Net proceeds of the transaction are intended to support eyonis® Lung Cancer Screening (LCS) Software as a Medical Device's commercial launch, sales ramp-up in U.S., as well as the expansion of the eyonis® suite of products for image-based early cancer diagnosis SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Not to be published, distributed or disseminated, directly or indirectly, in the United States of America, Australia, Canada, South Africa ...

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF's General Regulations.SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares 19,493,281 Number of real voting rights* (excluding treasury shares**) 19,409,273 Theoretical number of voting rights* (including treasury shares**) 19,470,081 (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF's General Regulations About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel...

Returns to FY revenue growth in 2024 (+3.3%), with acceleration in H2 (+10.2%) Slight decrease in operating loss, from €23.1 million in 2023 to €22.5 million in 2024 Operational improvements in H2 2024, to reduce cash burn and improve iCRO profitability, delivering full impact in 2025 Q1 2025 revenues up 11% over Q1 2024, order backlog at all-time high, €74.8 million as of March 31, 2025 eyonis™ Lung Cancer Screening (LCS) pivotal REALITY and RELIVE studies met all key endpoints U.S. FDA 510(k) filing in May 2025, CE marking filing expected in June. SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today reported its 2024 consolidated...

€6.0 million in Q1 2025 revenues, up 11% over Q1 2024 €74.8 million all-time high order backlog as of March 31, 2025 eyonis™ LCS pivotal RELIVE study met all key endpoints U.S. FDA 510(k) filing on track for May 2025, filing for CE marking expected in June 2025. eyonis™ LCS commercial launches as soon as year-end 2025 in U.S. and H1 2026 in Europe, pending regulatory approvals Cash and cash equivalents at €8.8 million as of March 31, 2025 SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”), manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, releases today its Q1 2025 key financial indicators (unaudited) and provides an update on Q1 operational achievements. Fredrik Brag, CEO and Founde...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: The shareholders of Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”) are invited to participate in the Shareholders' Extraordinary General Meeting which will be held on Thursday March 20, 2025, at 10:15 am CET at PDGB, 174 avenue Victor Hugo – 75116 Paris. All useful information relating to this Shareholders' General Meeting is regularly updated on Median Technologies' website. Shareholders may exercise their voting rights before the holding of the Shareholders' General Meeting, either by returning their postal voting form, or by giving proxy. The detailed procedures relating to the exercise of the right to vote are specified in the notice of the Shareholders' General Meeting, available here on Median's website The preliminary notice of the Shareholders' General Meeting has been published in the BALO (Bulletin des annonces légales obligatoires) on February 10, 2025, and has not been s...